- The disease
- Obstructive sleep apnea (OSA) is a condition in which the upper airway repeatedly collapses during sleep, causing breathing interruptions. It is associated with daytime sleepiness, cardiovascular stress, and reduced quality of life. OSA is measured using the apnea-hypopnea index (AHI), which counts breathing disruptions per hour of sleep. Moderate OSA is generally defined as an AHI of 15 to 30 events per hour (per AASM clinical guidelines).
- What the asset is trying to do
- SomnoDent Avant is a custom-fitted mandibular repositioning appliance (MRA) -- a removable oral device worn during sleep that holds the lower jaw (mandible) slightly forward. This forward positioning physically widens the upper airway, reducing the tendency for it to collapse. Unlike continuous positive airway pressure (CPAP), which delivers pressurised air through a mask, an MRA is a passive mechanical device with no external power source or tubing.
- What the trial is measuring, and why it matters
- The completed trial (NCT01588275) compared MRA therapy using SomnoDent against CPAP therapy in patients with moderate OSA. The trial enrolled a target of 86 participants (per ClinicalTrials.gov NCT01588275) and reached primary completion on 2017-12-31 (per ClinicalTrials.gov NCT01588275).
- Efficacy benchmarks in this setting
- In the moderate OSA setting, CPAP is an established standard of care. A randomised trial by Phillips et al. (Sleep, 2013) reported that both MRA and CPAP produced significant AHI reductions in moderate OSA patients, with CPAP achieving greater AHI reduction but MRA demonstrating non-inferior outcomes on neurobehavioural measures in that study population. Cairns et al. and other published comparisons have reported CPAP AHI reductions of approximately 75-80% from baseline in moderate OSA cohorts (per published literature; specific figures should be verified against the cited studies). Figures from the NCT01588275 trial for SomnoDent are from a completed study and are not statistically comparable to results from other trials conducted in different populations under different protocols.
- Commercial context
- SomnoDent Avant is a commercially available, TGA-listed (Australia) and FDA-cleared (United States) oral appliance for OSA; it is not an investigational product (per SomnoMed public disclosures). SomnoMed describes SomnoDent as its core commercial product line (per company investor presentations). The oral appliance therapy market for OSA operates alongside CPAP devices and surgical options, all of which are currently approved or cleared in major markets.